Literatur
- 1
Abou-Alfa G K, Schwartz L, Ricci S. et al .
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
J Clin Oncol.
2006;
24
4293-4300
- 2
Belfort R, Harrison S A, Brown K. et al .
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
N Engl J Med.
2006;
355
2297-2307
- 3
Berg T, von Wagner M, Nasser S. et al .
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks
of peginterferon-alfa-2a plus ribavirin.
Gastroenterology.
2006;
130
1086-1097
- 4
Chang T T, Gish R G, de Man R. et al .
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
N Engl J Med.
2006;
354
1001-1010
- 5
Chen C J, Yang H I, Su J. et al .
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B
virus DNA level.
JAMA.
2006;
295
65-73
- 6
Ekstedt M. et al .
Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Hepatology.
2006;
44
865-873
- 7
Erhardt A, Lorke J. et al .
Transient elastography for diagnosing liver cirrhosis.
Dtsch Med Wochenschr.
2006;
131
2765-1759
- 8
Folgori A, Capone S, Ruggeri L. et al .
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge
in chimpanzees.
Nat Med.
2006;
12
190-197
- 9
Haussinger D.
Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis.
Hepatology.
2006;
43
1187-1190
- 10
Iloeje U H, Yang H I, Su J. et al .
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Gastroenterology.
2006;
130
678-686
- 11
Kamath P S, Kim W R.
The model for end-stage liver disease (MELD).
Hepatology.
2007;
45
797-805
- 12
Lai C L, Shouval D, Lok A S. et al .
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
N Engl J Med.
2006;
354
1011-1020
- 13
Lok A S, McMahon B J.
Chronic hepatitis B.
Hepatology.
2007;
45
507-539
- 14
Mayo M J, Handem I, Saldana S. et al .
Sertraline as a first-line treatment for cholestatic pruritus.
Hepatology.
2007;
45
666-674
- 15
Ota T, Takamura T, Kurita S. et al .
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Gastroenterology.
2007;
132
282-293
- 16
Otto G, Herber S, Heise M. et al .
Response to transarterial chemoembolization as a biological selection criterion for
liver transplantation in hepatocellular carcinoma.
Liver Transpl.
2006;
12
1260-1267
- 17
Pares A, Caballeria L, Rodes J.
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical
response to ursodeoxycholic Acid.
Gastroenterology.
2006;
130
715-720
- 18
Prasad S, Dhiman R K. et al .
Lactulose improves cognitive functions and health-related quality of life in patients
with cirrhosis who have minimal hepatic encephalopathy.
Hepatology.
2007;
45
549-559
- 19
Rapti I, Dimou E et al.
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative
chronic hepatitis B.
Hepatology.
2007;
45
307-313
- 20
Sarrazin C, Rouzier R, Wagner F. et al .
SCH 503 034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon
alpha-2b for genotype 1 nonresponders.
Gastroenterology.
2007;
132
1270-1278
- 21
Schrier R W, Gross P, Gheorghiade M. et al .
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
N Engl J Med.
2006;
355
2099-2112
- 22
Sherman M, Yurdaydin C. et al .
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis
B.
Gastroenterology.
2006;
130
2039-2049
- 23
Shrestha M P, Scott R M. et al .
Safety and efficacy of a recombinant hepatitis E vaccine.
N Engl J Med.
2007;
356
895-903
- 24
Sudan D L.
Transplantation for cholangiocarcinoma.
Liver Transpl.
2006;
12
S83-84
- 25
van Bommel F, Zollner B, Sarrazin C. et al .
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection
and high HBV DNA level during adefovir therapy.
Hepatology.
2006;
44
318-325
- 26
Wedemeyer H, Cornberg M, Wiegand J, Manns M.
Treatment duration in acute hepatitis C: the issue is not solved yet.
Hepatology.
2006;
44
1051
- 27
Zeuzem S, Buti M, Ferenci P. et al .
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients
with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
J Hepatol.
2006;
44
97-103
- 28
Kettaneh A, Marcellin P, Douvin C. et al .
Features associated with success rate and performance of fibroscan measurements for
the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients.
J Hepatol.
2007;
46
628-634
Professor Dr. med. Robert Thimme
Medizinische Universitätsklinik Freiburg
Hugstetter Straße 55
79106 Freiburg
Phone: 0761/270-3401
Fax: 0761/270-3372
Email: robert.thimme@uniklinik-freiburg.de
